Olorofim Data Will Be Presented at IDWeek 2026
F2G Ltd. will share Phase 3 OASIS trial findings for its investigational antifungal at the conference this October.
Updated on Oct. 6, 2026 in Asthma
Live Poll
Would you participate in a clinical trial for a life-threatening infection with limited treatment options?
F2G Ltd. will present findings from its Phase 3 OASIS clinical trial on October 22, 2026, during the IDWeek conference in Washington, D.C. The study evaluates the efficacy of the investigational therapy olorofim in treating invasive aspergillosis.
Why it matters
Invasive aspergillosis currently faces limited treatment options due to drug resistance and toxicity concerns. If approved, olorofim would represent the first novel mechanism agent for the infection in more than two decades.
The OASIS trial randomized 225 subjects to evaluate olorofim using a 20% non-inferiority margin. Study 32 protocols required patients to take 150 mg on day one followed by 90 mg BID oral doses for a 90-day treatment duration.
The players
F2G Ltd.
This biopharmaceutical company headquartered in Manchester, United Kingdom, focuses on developing novel treatments for life-threatening fungal infections.
FDA
The Food and Drug Administration is the federal agency responsible for overseeing the safety and efficacy of medical products in the United States.
The details
The OASIS trial compares the efficacy of oral olorofim against AmBisome, a standard treatment, for patients suffering from invasive aspergillosis. While the drug has received orphan drug, QIDP, and two Breakthrough Therapy designations from the FDA, it is not yet approved for medical use.
Timeline
June 2018: Study 32 enrollment began.
September 2022: Study 32 enrollment concluded.
October 21-24, 2026: IDWeek 2026 conference takes place.
October 22, 2026: Oral presentation of OASIS data.
October 24, 2026: Poster session regarding quality of life outcomes.
The Big Picture
The presentation of these results at IDWeek 2026 follows the standard pattern of pharmaceutical companies using major medical conferences to disclose significant Phase 3 clinical trial data. This event serves as a major forum for infectious disease research and clinical advancements.
Patients currently dealing with resistant fungal infections should note that olorofim remains an investigational therapy without regulatory approval. Access to this treatment is currently limited to clinical trial settings until further FDA review occurs.
The takeaway
The development of novel antifungal agents is critical as clinicians struggle with increasing rates of drug-resistant infections. Continued monitoring of regulatory filings is necessary to determine when or if this treatment may become available for public use.
Further reading
Learn more about respiratory and infectious disease research in the Asthma section.
More information
View the Study 32 clinical trial details for comprehensive data on the study protocol.
Live Poll
Would you participate in a clinical trial for a life-threatening infection with limited treatment options?
